Spun out of King’s College London, AviadoBio is focusing on neurodegenerative diseases and has emerged from stealth with nearly $100m in overall funding.

AviadoBio, a UK-based neurodegenerative gene therapy developer spun out King’s College London, picked up $80m in a series A round co-led by New Enterprise Associates and Monograph Capital yesterday.

Johnson & Johnson Innovation – JJDC and F-Prime Capital, respective vehicles for healthcare group Johnson & Johnson and financial services provider Fidelity, contributed to the round, as did LSP, Advent Life Sciences, Dementia Discovery Fund (DDF) and LifeArc.

Founded in 2019, AviadoBio is working on gene therapies for neurodegenerative conditions including…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).